Acute lymphoblastic leukaemia develops in both children and adults, with a peak incidence
between 1 year and 4 years. Most acute lymphoblastic leukaemia arises in healthy …

Abstract The updated International Consensus Classification (ICC) of B-acute lymphoblastic
leukemia (B-ALL) and T-acute lymphoblastic leukemia (T-ALL) includes both revisions to …

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy.
Advancements in technology that enhance our understanding of the biology of the disease …

Blinatumomab, a bispecific antibody that directs CD3+ T cells to CD19+ tumor cells, shows
variable efficacy in B-progenitor acute lymphoblastic leukemia (B-ALL). To determine tumor …

Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies
characterized by abnormal proliferation of immature lymphoid cells. It is the most commonly …

Acute lymphoblastic leukemia (ALL) is characterized by genetic alterations that block
differentiation, promote proliferation of lymphoid precursor cells, and are important for risk …

Interleukin-7 receptor α (encoded by IL7R) is essential for lymphoid development. Whether
acute lymphoblastic leukemia (ALL)-related IL7R gain-of-function mutations can trigger …

Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like ALL; BCR-ABL1–like
ALL) in children with National Cancer Institute (NCI) intermediate-or high-risk (HR) ALL is …

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and constitutes
approximately 25% of cancer diagnoses among children under the age of 15 (Howlader et …

Ruxolitinib is the first approved JAK1 and JAK2 inhibitor, and is known to interfere with the
JAK/STAT signaling pathway, one of the critical cellular signaling pathways involved in the …